---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033556"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:08:51.253253+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%

## Summary
- Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).
- FY2024 net loss $51.5M ($1.03/shr) vs $55.5M ($1.14/shr) prior; cash used $17.8M (62% improvement YoY).
- FY2025 revenue guidance $70M-$75M (6%-12% decline) citing new Medicare LCDs restricting MIGS coverage with cataract.
- Adj. operating expenses FY2025 guided $105M-$107M (+4-6%); next-gen OMNI expected H1 2025.
- Gross margin Q4 87% vs 85% prior; cash and equivalents $120.4M at Dec 31, 2024.

## SEC filing metadata
- accession: 0000950170-25-033556
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/0000950170-25-033556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017025033556/sght-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033556
- JSON: https://secwatch.observer/filing/0000950170-25-033556.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.